Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Terminated 2Completed 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 10Recurrence 5Leukemia, Myelomonocytic, Chronic 4Leukemia 4Lymphoma, T-Cell, Peripheral 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Hematologic Neoplasms 2Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myeloid 1Glioma 1Frailty 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

blinatumomab 2Carboplatin 2venetoclax 1treosulfan 1flumatinib 1fludarabine phosphate 1anlotinib 1aflutinib 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Neoadjuvant Therapy 1Maintenance 1Interferon alpha-2 1Inotuzumab Ozogamicin 1Injections 1Immunotherapy 1Drug Therapy 1Docetaxel 1Decitabine 1Cytarabine 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Carmustine 1Busulfan 1Bortezomib 1Blood Specimen Collection 1Azacitidine 1Anti-Inflammatory Agents, Non-Steroidal 1Adjuvants, Pharmaceutic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasm, Residual × Azacitidine × Clear all
NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Beijing 302 Hospital

Phase 2 Unknown
52 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡